Literature DB >> 8472363

Enzyme immunoassay--a new technique for estimating hemoglobin A1c.

W G John1, M R Gray, D L Bates, J L Beacham.   

Abstract

We describe a method for estimating hemoglobin A1c (HbA1c) with a commercially available enzyme immunoassay system. The method is based on microtiter plate technology, utilizing an antibody raised to hemoglobin, the epitope being the Amadori product of glucose plus the first eight amino acids on the N-terminal end of the beta chain of hemoglobin. The enzyme immunoassay displays good within-batch (CV 2.3-2.4%) and between-batch (CV 2.6-5.0%) precision, and the results were not affected by different types of anticoagulant. The method was linear within the expected range of results and showed good correlation (r = 0.88-0.98) with established methods for estimating glycohemoglobin. Using this method, we obtained a reference interval of 2.8-4.9% (central 95%) for HbA1c in a nondiabetic population. The percentages of hemoglobin that were HbA1c in diabetics (6.86% +/- 2.51%) were significantly greater (P < 0.001) than in nondiabetics (3.46% +/- 0.52%).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472363

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  16 in total

1.  Immunoturbidimetric assay of glycated hemoglobin.

Authors:  P Metus; N Ruzzante; P Bonvicini; M Meneghetti; M Zaninotto; M Plebani
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus.

Authors:  D R Witte; S Tesfaye; N Chaturvedi; S E M Eaton; P Kempler; J H Fuller
Journal:  Diabetologia       Date:  2004-12-24       Impact factor: 10.122

Review 3.  A review of the challenge in measuring hemoglobin A1c.

Authors:  Cas Weykamp; W Garry John; Andrea Mosca
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

4.  Crystallization and preliminary crystallographic analysis of two eukaryotic fructosyl peptide oxidases.

Authors:  Atsushi Ichiyanagi; Kozo Hirokawa; Keiko Gomi; Toru Nakatsu; Hiroaki Kato; Naoki Kajiyama
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-01-30

5.  Complications and cardiovascular risk factors in insulin-dependent diabetes--findings in an Irish clinic and in other European centres.

Authors:  C C Cronin; J B Ferriss; J M Stephenson; B Crowley; A Whyte; P E Cleary
Journal:  Ir J Med Sci       Date:  1994-11       Impact factor: 1.568

6.  Do European people with type 1 diabetes consume a high atherogenic diet? 7-year follow-up of the EURODIAB Prospective Complications Study.

Authors:  Sabita S Soedamah-Muthu; Nish Chaturvedi; John H Fuller; Monika Toeller
Journal:  Eur J Nutr       Date:  2012-12-07       Impact factor: 5.614

7.  Towards worldwide standardisation of HbA1c determination.

Authors:  K Miedema
Journal:  Diabetologia       Date:  2004-07-13       Impact factor: 10.122

8.  Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study.

Authors: 
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

9.  Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study.

Authors:  F Giorgino; L Laviola; P Cavallo Perin; B Solnica; J Fuller; N Chaturvedi
Journal:  Diabetologia       Date:  2004-05-29       Impact factor: 10.122

10.  Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS).

Authors:  S S Soedamah-Muthu; N Chaturvedi; J C Pickup; J H Fuller
Journal:  Diabetologia       Date:  2008-01-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.